Get started

Pharmastocks

LUPIN BUY (LONG)Lupin is a BUY at CMP@1470 with SL@1420 for a target of TP@1600 Lupin gets USFDA nod to market pain relief, colonoscopy drugs and also gets FDA approval for generic Percocet tablets . Lupin recently received FDA approval for generic Suprep Bowel Prep Kit and Suprep kit approval It may add 5% to Lupin’s EPS for FY18 earnings. In addition the pharma major’s Goa facility has been cleared by the US FDA. Lupin Result: Revenue grew 26% YoY to INR 44.8b Gross margin was stable QoQ at 71.0%. EBITDA rose 27% YoY to INR 12.2b with margin of 27% . EBITDA margin improvement was primarily driven by strong growth in US sales (+53% YoY, +8% QoQ; despite R&D as % of sales at 12.9%) and forex gain of INR 270m. PAT of INR 6.3b was impacted by 1% due to a high tax rate of 39%. Lupin is a BUY at CMP@1470 with SL@1420 for a target of TP@1600
NSE:LUPINLong
by VIRUSSOUL